English

Biohit Oyj starts inviting participants in the confirmatory smoking intervention trial

Report this content

Biohit Oyj Press Release April 14, 2016 at 9:30 am local time (EEST)
 

Biohit Oyj starts inviting the smoking volunteers in the confirmatory smoking intervention trial. The clinical confirmatory trial has obtained ethical approval from the regional ethical committee requested from all clinical studies before they can be started.

The test compound is Acetium lozenge binding acetaldehyde in the saliva into a harmless compound. The aim of the confirmatory study is to affirm the promising results obtained in the previous smoking intervention trial with Acetium lozenge. If successful, the trial gives adequate power to confirm, that the Acetium lozenge represents a breakthrough in the development of smoking intervention methods.

Enrollment for the study has begun

Persons who may be suitable for the study 

  • are males or females aged 18-65 years 
  • smoke regularly (only cigarettes) 
  • want to quit smoking 
  • have no serious smoking related illnesses (such as chronic obstructive pulmonary disease, lung cancer) 
  • are not pregnant or breastfeeding 
  • are not part of another clinical trial 
  • don’t use any prescription medication for smoking cessation 
  • have not been part of the first smoking intervention trial by Biohit

Enrollment (only in Finland) is available online at Kuulas Helsinki: http://www.kuulas.fi, by phone 040 6792451 or by email contact@kuulas.fi.

A cohort of 1,800 active smokers motivated to quit will be invited in the study. The study will be conducted as a randomized, placebo-controlled, double-blind clinical trial, where half of the subjects will receive the active compound and the other half will receive a placebo. The study is conducted in cooperation with research agency Kuulas Helsinki and the study covers whole Finland.

CEO Semi Korpela, Biohit Oyj: ‘Enrollment of smoking volunteers in the trial will start immediately.’

The person-in-charge of the study is the Chief Medical Director of Biohit Oyj, MD, PhD, Professor Kari Syrjänen. The principal investigator at Kuulas Helsinki is Adjunct Professor, D.Soc.Sc., Anna Bäckström.

 

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Press Release February 15, 2016: Biohit Oyj starts a confirmatory smoking intervention trial

 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Subscribe